These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 22952439)

  • 21. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study.
    Gobena D; Ameya G; Haile K; Abreha G; Worku Y; Debela T
    Ann Clin Microbiol Antimicrob; 2018 Jul; 17(1):30. PubMed ID: 29970076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
    Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
    PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study.
    Hirpa S; Medhin G; Girma B; Melese M; Mekonen A; Suarez P; Ameni G
    BMC Public Health; 2013 Aug; 13():782. PubMed ID: 23981845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.
    Fox GJ; Mitnick CD; Benedetti A; Chan ED; Becerra M; Chiang CY; Keshavjee S; Koh WJ; Shiraishi Y; Viiklepp P; Yim JJ; Pasvol G; Robert J; Shim TS; Shin SS; Menzies D; ; Ahuja S; Ashkin D; Avendaño M; Banerjee R; Bauer M; Burgos M; Centis R; Cobelens F; Cox H; D'Ambrosio L; de Lange WCM; DeRiemer K; Enarson D; Falzon D; Flanagan K; Flood J; Gandhi N; Garcia-Garcia L; Granich RM; Hollm-Delgado MG; Holtz TH; Hopewell P; Iseman M; Jarlsberg LG; Kim HR; Lancaster J; Lange C; Leimane V; Leung CC; Li J; Menzies D; Migliori GB; Narita M; Nathanson E; Odendaal R; O'Riordan P; Pai M; Palmero D; Park SK; Pena J; Pérez-Guzmán C; Ponce-de-Leon A; Quelapio MID; Quy HT; Riekstina V; Royce S; Salim M; Schaaf HS; Seung KJ; Shah L; Shean K; Sifuentes-Osornio J; Sotgiu G; Strand MJ; Sung SW; Tabarsi P; Tupasi TE; Vargas MH; van Altena R; van der Walt M; van der Werf TS; Westenhouse J; Yew WW
    Clin Infect Dis; 2016 Apr; 62(7):887-895. PubMed ID: 26757804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study.
    Panford V; Kumah E; Kokuro C; Adoma PO; Baidoo MA; Fusheini A; Ankomah SE; Agyei SK; Agyei-Baffour P
    BMJ Open; 2022 Jul; 12(7):e062857. PubMed ID: 35790328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.
    Mulu W; Mekonnen D; Yimer M; Admassu A; Abera B
    Afr Health Sci; 2015 Jun; 15(2):368-77. PubMed ID: 26124781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
    Pietersen E; Anderson K; Cox H; Dheda K; Bian A; Shepherd BE; Sterling TR; Warren RM; van der Heijden YF
    PLoS One; 2023; 18(2):e0281097. PubMed ID: 36780443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of ethnic disparities on the treatment outcomes of HIV-negative drug-resistant tuberculosis patients in Kuala Lumpur, Malaysia: A call for a culturally-sensitive community intervention approach.
    Shariff NM; Shah SA; Kamaludin F
    J Glob Antimicrob Resist; 2019 Dec; 19():274-279. PubMed ID: 31100500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
    Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
    Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sector.
    Jeon DS; Shin DO; Park SK; Seo JE; Seo HS; Cho YS; Lee JY; Kim DY; Kong SJ; Kim YS; Shim TS
    J Korean Med Sci; 2011 Jan; 26(1):33-41. PubMed ID: 21218027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.
    Velásquez GE; Becerra MC; Gelmanova IY; Pasechnikov AD; Yedilbayev A; Shin SS; Andreev YG; Yanova G; Atwood SS; Mitnick CD; Franke MF; Rich ML; Keshavjee S
    Clin Infect Dis; 2014 Jul; 59(1):9-15. PubMed ID: 24729493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.
    Cavanaugh JS; Kazennyy BY; Nguyen ML; Kiryanova EV; Vitek E; Khorosheva TM; Nemtsova E; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1069-74. PubMed ID: 22691694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.